How is King Charles’ cancer treatment? Doctors and royal family weigh in
He underwent treatment for a benign condition last month.
He underwent treatment for a benign condition last month.
Scientific detective work helped transform a previously shelved drug into a medicine now approved for relapsed or progressive pediatric low-grade glioma.
Moffitt patient loses her mother to cancer two years after her own diagnosis
Mohamad Mohty, MD, PhD, highlights key takeaways from the 50th Annual EMBT Meeting, focusing on ongoing efforts within the GVHD treatment arena.
UGN-102 with/without TURBT displayed meaningful and similar DFS and DOR rates in newly diagnosed and recurrent low-grade intermediate-risk NMIBC.
Dr. Parker and colleagues report in the current issue of Annals of Oncology the updated results of the RADICALS-RT randomized trial evaluating the superiority of…
In this episode “ASTCT Talks,” hosts Rebecca Epperly, MD, and Aimee Talleur, MD, from St. Jude Children’s Research Hospital, dive into the pioneering realm of…
Cretostimogene grenadenorepvec elicited durable responses in high-risk BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ.
The OncoAlert Newsletter is now out for June 23-29, 2023
The CAR T-cell therapy NXC-201 has received orphan drug designation by the European Commission for patients with multiple myeloma.
Erin Frances Cobain, MD, discusses unanswered questions regarding the use of ribociclib and immunotherapy in early-stage breast cancer.